



# IP Receptor siRNA (h): sc-40175

## BACKGROUND

Cyclooxygenases metabolize arachidonate to five primary prostanoids: PGE<sub>2</sub>, PGF<sub>2</sub>α, PGI<sub>2</sub>, TXA<sub>2</sub> and PGD<sub>2</sub>. These lipid mediators interact with specific members of G protein-coupled prostanoid receptors, designated EP, FP, IP, TP and DP, respectively. The IP Receptor binds prostacyclin, PGI<sub>2</sub>, the main prostanoid synthesized by vascular tissues. First discovered in 1976, prostacyclin is involved in platelet aggregation inhibition, vasodilatation and cytoprotection, and either prostacyclin or its analogs are used in the treatment of hypertension. Upon binding to the IP Receptor, prostacyclin activates adenylate cyclase primarily through the Gas protein. The gene encoding the human IP Receptor is located on chromosome 19. It is expressed as a glycosylated and phosphorylated protein, which is abundantly expressed in vascular tissues such as aorta, lung, atrium and ventricle, as well as in kidney, thymus, spleen and neurons.

## REFERENCES

1. Botting, R., et al. 1989. Vasoactive mediators derived from the endothelium. *Arch. Mal. Coeur. Vais.* 82: 11-14.
2. Grant, S.M., et al. 1992. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. *Drugs* 43: 889-924.
3. Nakagawa, O., et al. 1994. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. *Circulation* 90: 1643-1647.
4. Vane, J.R., et al. 1995. Pharmacodynamic profile of prostacyclin. *Am. J. Cardiol.* 75: 3-10.
5. Ogawa, Y., et al. 1995. Structural organization and chromosomal assignment of the human prostacyclin receptor gene. *Genomics* 27: 142-148.
6. Oida, H., et al. 1995. *In situ* hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. *Br. J. Pharmacol.* 116: 2828-2837.
7. Smyth, E.M., et al. 1996. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. *J. Biol. Chem.* 271: 33698-33704.
8. Breyer, R.M., et al. 2001. Prostanoid receptors: subtypes and signaling. *Annu. Rev. Pharmacol. Toxicol.* 41: 661-690.

## CHROMOSOMAL LOCATION

Genetic locus: PTGIR (human) mapping to 19q13.32.

## PRODUCT

IP Receptor siRNA (h) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see IP Receptor shRNA Plasmid (h): sc-40175-SH and IP Receptor shRNA (h) Lentiviral Particles: sc-40175-V as alternate gene silencing products.

## STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μl of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μl of RNase-free water makes a 10 μM solution in a 10 μM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

## APPLICATIONS

IP Receptor siRNA (h) is recommended for the inhibition of IP Receptor expression in human cells.

## SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μM in 66 μl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## GENE EXPRESSION MONITORING

IP Receptor (B-6): sc-515139 is recommended as a control antibody for monitoring of IP Receptor gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

## RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor IP Receptor gene expression knockdown using RT-PCR Primer: IP Receptor (h)-PR: sc-40175-PR (20 μl, 568 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.